Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.60 |
| ▸ | ACVR1 | Q04771 | 12/20 | 0.56 |
| ▸ | BMPR1B | O00238 | 10/20 | 0.56 |
| ▸ | ACVRL1 | P37023 | 10/20 | 0.56 |
| ▸ | BMPR1A | P36894 | 10/20 | 0.56 |
| ▸ | BMP4 | P12644 | 4/20 | 0.56 |
| ▸ | ACVR1B | P36896 | 11/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.55 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.55 |
| ▸ | BMPR2 | Q13873 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988922 | 0.85 | KDR (0.54) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL12779951 | 0.84 | ACVRL1 (0.78) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL23988864 | 0.84 | KDR (0.59) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL23988808 | 0.84 | KDR (0.58) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL23988686 | 0.84 | KDR (0.58) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL16743057 | 0.84 | ACVR1 (0.74) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL23988753 | 0.83 | KDR (0.55) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL23989024 | 0.83 | ACVR1 (0.69) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL12779920 | 0.83 | BMP4 (0.82) | KDRACVR1BMPR1BACVRL1BMPR1A | |
| SCHEMBL12779952 | 0.83 | KDR (0.60) | KDRACVR1BMPR1BACVRL1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |